Get started
Author

Alessia Campagna

Observed names: A. Campagna, Campagna, Alessia
Observed institutions: Humanitas University, Ministero della Salute, Azienda Ospedaliera Sant'Andrea, Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS Humanitas Research Hospital, Sapienza University of Rome
ORCID: 0000-0002-8481-759X
Observed ORCID: 0000-0002-8481-759X
OpenAlex ID: A5022290442
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
2021 · Matteo Bersanelli, Erica Travaglino, et al. · Journal of Clinical Oncology · 222
PDF
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
2023 · Elisabetta Sauta, Marie Robin, et al. · Journal of Clinical Oncology · 122
PDF
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
2023 · Saverio D'Amico, Daniele Dall’Olio, et al. · JCO Clinical Cancer Informatics · 95
PDF
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years
2021 · Marianna Rossi, Manja Meggendorfer, et al. · Blood · 70
PDF
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
2024 · Cristina Astrid Tentori, Caterina Gregorio, et al. · Journal of Clinical Oncology · 48
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
2022 · Giulia Maggioni, Matteo Bersanelli, et al. · The Lancet Haematology · 34
A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review
2019 · Monica Piedimonte, Tiziana Ottone, et al. · BMC Cancer · 34
PDF
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
2024 · Rami S Komrokji, Luca Lanino, et al. · The Lancet Haematology · 31
PDF
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
2024 · Maria Julia Montoro, Laura Palomo, et al. · Blood · 31
MOSAIC: An Artificial Intelligence–Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers
2024 · Saverio D'Amico, Lorenzo Dall’Olio, et al. · JCO Clinical Cancer Informatics · 23
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
2025 · Matteo Zampini, Elena Riva, et al. · Journal of Clinical Oncology · 20
Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
2025 · Angela Consagra, Luca Lanino, et al. · HemaSphere · 14
PDF
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment
2019 · Roberto Latagliata, Pasquale Niscola, et al. · Hematological Oncology · 10
A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches
2020 · Paolo Bossi, Mario Airoldi, et al. · Expert Opinion on Drug Safety · 9
PDF
Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
2018 · Ambra Di Veroli, Alessia Campagna, et al. · Leukemia Research · 9
An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia
2024 · Gianluca Asti, Saverio D'Amico, et al. · Blood · 8
PDF
A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
2024 · Saverio D'Amico, Elisabetta Sauta, et al. · Blood · 5
PDF
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)
2023 · Cristina Astrid Tentori, Caterina Gregorio, et al. · Blood · 5
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
2022 · Alessia Campagna, Daniela De Benedittis, et al. · Journal of Clinical Medicine · 5
PDF
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
2026 · Luca Lanino, Anthony M. Hunter, et al. · Journal of Clinical Oncology · 4
PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression
2026 · Veronica Vallelonga, Francesco Gandolfi, et al. · Blood · 4
PDF
Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing
2023 · Gianluca Asti, Elisabetta Sauta, et al. · Blood · 4
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
2022 · Elisabetta Sauta, Marie Robin, et al. · Blood · 4
Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation
2019 · Alessia Campagna, Valentina Gianfelici, et al. · Bone Marrow Transplantation · 4
Longitudinal Synthetic Data Generation by Artificial Intelligence to Accelerate Clinical and Translational Research in Breast Cancer
2025 · Elena Zazzetti, Saverio D'Amico, et al. · JCO Clinical Cancer Informatics · 3
Works count: 86
Citation count: 867
H-index: 12
I10-index: 13
Year
Topic
Type